| Identification | Back Directory | [Name]
BroMosporine | [CAS]
1619994-69-2 | [Synonyms]
BroMosporine
N-[6-(3-Methanesulfonamido-4-methylphenyl)-3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-8-yl]carbamate
ethyl 3-Methyl-6-(4-Methyl-3-(MethylsulfonaMido)phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-8-ylcarbaMate | [Molecular Formula]
C17H20N6O4S | [MDL Number]
MFCD26142669 | [MOL File]
1619994-69-2.mol | [Molecular Weight]
404.443 |
| Chemical Properties | Back Directory | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
Soluble in DMSO (up to 25 mg/ml) | [form ]
solid | [pka]
6.21±0.46(Predicted) | [color ]
Off-white | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| Hazard Information | Back Directory | [Description]
Bromosporine (1619994-69-2) is a potent pan-Bromodomain (BRD) inhibitor.1?Bromosporine was able to reactivate HIV-1 replication in different latency models.2 | [Uses]
Bromosporine is a broad spectrum inhibitor for bromodomains. | [target]
bromodomain | [storage]
Store at +4°C | [References]
1) Picaud?et al.?(2016),?Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia; Sci. Adv.?2?e1600760
2) Pan?et al.?(2017),?The bromodomain and extraterminal domain inhibitor bromosporine synergistically reactivates latent HIV-1 in latently infected cells; Oncotarget?8?94104 |
|
|